Company Overview More
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
CEO: Tuchman M.D., MBA(FAAN), Alan J.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > SNPX Synaptogenix > Detailed Quotes

SNPX Synaptogenix

4.830+0.170+3.65%
Close 05/16 20:00 ET
High
4.900
Open
4.815
Turnover
107.27K
Low
4.690
Pre Close
4.660
Volume
22.40K
Market Cap
32.89M
P/E(TTM)
Loss
52wk High
14.500
Shares
6.81M
P/E(Static)
Loss
52wk Low
3.790
Float Cap
30.30M
Bid/Ask %
-100.00%
Historical High
14.500
Shs Float
6.27M
Volume Ratio
0.24
Historical Low
3.560
Dividend TTM
--
Div Yield TTM
--
P/B
1.04
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.36%
Amplitude
4.51%
Avg Price
4.789
Lot Size
1
Float Cap
30.30M
Bid/Ask %
-100.00%
Historical High
14.500
Shs Float
6.27M
Volume Ratio
0.24
Historical Low
3.560
Dividend TTM
--
P/B
1.04
Dividend LFY
--
Turnover Ratio
0.36%
Amplitude
4.51%
Avg Price
4.789
Lot Size
1
Price Forecast

Loading...

News

Comment